IXICO Wins £1.5m Contract Extension on Phase 2 Huntington’s Trial

An announcement from IXICO plc ( (GB:IXI) ) is now available.

IXICO plc, a London-listed neuroscience imaging and biomarker analytics company, has secured an extension to an existing contract with a leading international pharmaceutical client, tied to the continued progress of a Phase 2 Huntington’s disease clinical trial. The expanded mandate underscores the appeal of its AI-driven IXI platform and deep neurological disease expertise for global biopharma customers seeking robust imaging support.

The extension is expected to deliver around £1.5 million in additional revenue over the next three years, enhancing IXICO’s visibility on mid-term income from its specialist role in neurological drug development. Management framed the deal as evidence that its technology and scientific capabilities are delivering “gold standard” outcomes, reinforcing IXICO’s positioning within the competitive imaging CRO market and providing greater operational and commercial stability as trials advance.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

Spark’s Take on GB:IXI Stock

According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.

IXICO plc’s stock score is primarily driven by its financial performance challenges, including consistent net losses and negative cash flows. However, positive earnings call sentiment and technical indicators suggest potential for future growth. Valuation remains a concern due to ongoing losses.

To see Spark’s full report on GB:IXI stock, click here.

More about IXICO plc

IXICO plc is a London-based neuroscience imaging and biomarker analytics specialist that operates as an end-to-end imaging contract research organisation. Using its proprietary AI-driven IXI platform, it supports global pharmaceutical and biotech clients in neurological drug discovery and development, particularly in diseases such as Alzheimer’s, Huntington’s and Parkinson’s. The company has a 20-year track record, has supported hundreds of neurological clinical trials and built a worldwide network of expert imaging centres. Its platform is tailored to process imaging data from global trials, quantify key biomarkers and translate complex data into clinically meaningful insights while reducing variability and improving reproducibility.

Average Trading Volume: 67,795

Technical Sentiment Signal: Strong Sell

Current Market Cap: £9.5M

Learn more about IXI stock on TipRanks’ Stock Analysis page.